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We aimed to assess intrinsic smooth muscle mechanisms contributing
to greater nitric oxide (NO) responsiveness in pulmonary vascular vs.
airway smooth muscle. Porcine pulmonary artery smooth muscle
(PASM) and tracheal smooth muscle (TSM) strips were used in
concentration-response studies to the NO donor (Z)-1-[N-2-aminoethyl-
N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO).
PASM consistently exhibited greater relaxation at a given DETA-NO
concentration (NO responsiveness) than TSM NO responsiveness,
with DETA-NO log EC50 being 6.55  0.11 and 5.37  0.13 for
PASM and TSM, respectively (P  0.01). We determined relation-
ships between tissue cGMP concentration ([cGMP]i) and relaxation
using the particulate guanylyl cyclase agonist atrial natriuretic pep-
tide. Atrial natriuretic peptide resulted in nearly complete relaxation,
with no detectable increase in [cGMP]i in PASM and only 20%
relaxation (10-fold increase in [cGMP]i) in TSM, indicating that TSM
is less cGMP responsive than PASM. Total cGMP-dependent protein
kinase I (cGKI) mRNA expression was greater in PASM than in TSM
(2.23  0.36 vs. 0.93  0.31 amol mRNA/g total RNA, respec-
tively; P  0.01), but total cGKI protein expression was not signifi-
cantly different (0.56  0.07 and 0.49  0.04 ng cGKI/g protein,
respectively). The phosphotransferase assay for the soluble fraction of
tissue homogenates demonstrated no difference in the cGMP EC50
between PASM and TSM. The maximal phosphotransferase activity
indexed to the amount of total cGKI in the homogenate differed
significantly between PASM and TSM (1.61  0.15 and 1.04 
pmol min1 ng cGKI1, respectively; P  0.05), suggesting that
cGKI may be regulated differently in the two tissues. A novel intrinsic
smooth muscle mechanism accounting for greater NO responsiveness
in PASM vs. TSM is thus greater cGMP responsiveness from in-
creased cGKI-specific activity in PASM.
cGMP-dependent protein kinase
AIRWAY SMOOTH MUSCLE IS LESS responsive to exogenously
administered nitric oxide (NO) and NO donors than the pul-
monary arterial circulation (3, 22). In addition, concentrations
of inhaled NO or of intravenously administered NO donors,
which dramatically reduce pulmonary vascular resistance, have
little beneficial effect on airway constriction (14, 18, 21). Our
group (22) recently demonstrated that pulmonary artery
smooth muscle (PASM) was more sensitive to relaxation by
NO than tracheal smooth muscle (TSM) and that this was
associated with greater intracellular cGMP levels ([cGMP]i) at
a given NO donor concentration. This finding was correlated
with greater expression and activity of the enzyme responsible
for NO-induced cGMP production, soluble guanylyl cyclase
(sGC), in PASM (22). An additional mechanism that could
contribute to these observations, an increased cGMP respon-
siveness in PASM vs. TSM, could not be addressed in those
studies because 90% of NO-induced relaxation took place
with no detectable increase in steady-state [cGMP]i.
[cGMP]i plays a variety of roles in the smooth muscle cell,
most of them mediated by cGMP-dependent protein kinases
(cGK), with the salient cGMP-cGK-mediated mechanism for
smooth muscle relaxation related to reductions in myoplasmic
Ca2 (10) and in the sensitivity of myofilament contractile
proteins to Ca2 (31, 33, 38). Two genes, coding for cGK type
I (cGKI) and type II (cGKII), have been identified in mammals
(8). cGKII is a membrane-bound protein that is abundantly
expressed in lung (16, 43), although its presence in smooth
muscle from lung has not been determined. cGKI is a soluble
protein that largely exists as a homodimer in tissues and
catalyzes transfer of the -phosphate from ATP to a consensus
sequence found on a variety of proteins (24). The NH2 termi-
nus of cGKI is encoded by an alternatively spliced exon 1 (30),
giving rise to the two cGK isoforms known to exist in smooth
muscle, cGKI and cGKI	, which have the COOH-terminal
583 amino acids in common (34, 39, 44). The two cGKI
isoforms are maximally activated to the same extent by cGMP,
but cGKI	 requires 10-fold higher [cGMP] than cGKI to
achieve this degree of activation (23, 36).
Comparison of the cGMP responsiveness between two dif-
ferent tissues using cGK agonists is challenging because the
contribution of variable tissue permeability to relaxant effects
between tissues is difficult to ascertain. Particulate guanylyl
cyclases, such as the natriuretic peptide receptor A, are another
enzyme system that increases [cGMP]i and account for the
relaxant effect of atrial natriuretic peptide (ANP) in smooth
muscle (9). Previous work has suggested that, although ANP
significantly increases [cGMP]i in TSM, it results in only
modest relaxation (33). This suggests the possibility that an
endogenous rather than exogenous cGMP source may be used
to further explore the possibility of different cGMP respon-
siveness between PASM and TSM.
In the present study, we determined the effect of ANP on
[cGMP]i and isometric force during continuous contraction of
PASM and TSM. We tested the hypothesis that the cGMP
responsiveness of PASM is greater than that of TSM because
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of greater cGKI expression and phosphotransferase activity in
the former tissue. In the course of these studies, total cGKI
mRNA and protein expression and the cGMP concentration
dependence of phosphotransferase activity were semiquantita-
tively determined in these tissues for the first time.
MATERIALS AND METHODS
Tissue preparation. After Institutional Animal Care and Use Com-
mittee approval was received, pigs (domestic crossbreds, weight
35–77 kg) were anesthetized with intravenous pentobarbital sodium
(100 mg/kg) and exsanguinated by bilateral transection of the carotid
arteries. The extrathoracic trachea and lungs were excised and im-
mersed in chilled physiological salt solution with a composition (in
mM) of 110.5 NaCl, 25.7 NaHCO3, 5.6 dextrose, 3.4 KCl, 2.4 CaCl2,
1.2 KH2PO4, and 0.8 MgSO4. Third-generation pulmonary artery was
dissected from the lung parenchyma, cut into rings, and cleaned of
adventitia under microscopic observation; the endothelium was then
removed by gentle rubbing of the luminal surface with a moist cotton
swab. The fat, connective tissue, and the epithelium of TSM were
removed with tissue forceps and scissors under microscopic observa-
tion to make muscle strips. For isometric force measurements, strips
of each type of smooth muscle were prepared of 0.1–0.2 mm width,
1 cm length, and 0.2–0.3 mg wet wt. The NO responsiveness of first-
to fourth-generation pulmonary arteries was not significantly different
(unpublished observations), and third-generation pulmonary artery
was used in these studies because of ease of preparation and better
definition of myocyte orientation. Higher generation airways were not
used because of difficulties in separating epithelial cells from smooth
muscle cells, which was undesirable in the biochemical and expres-
sion studies.
Mechanical measurements. Strips were suspended in 5-ml tissue
baths filled with physiological salt solution (37°C) aerated with 94%
O2-6% CO2, pH 7.4. One end of the strips was anchored to a metal
hook at the bottom of the tissue bath; the other end was attached to a
calibrated force transducer (model FT03D; Grass Instruments/Astro-
Med, West Warwick, RI). During a 3-h equilibration period, the strips
were repeatedly contracted isometrically using 40 mM KCl and then
relaxed. The length of the strips was increased after each contraction-
relaxation cycle until active force was maximal (optimal length). All
strips were subsequently maintained at optimal length. Relaxed
PASM strips were then contracted with norepinephrine (1 M), and
the absence of endothelium was verified by failure of acetylcholine (1
M) to cause relaxation. Strips were then relaxed again until com-
mencement of a study. Before concentration-response studies, all
strips were incubated with 10 M indomethacin to prevent the
formation of prostanoids. In previous studies, contraction of TSM and
PASM during incubation with indomethacin had no effect on tissue
[cGMP]i (17).
Concentration-response curves. The concentration responses of
TSM and PASM to the NO donor were performed 15 min after an
isometric contraction with isotonic KCl. KCl was used rather than
receptor agonists to avoid possible differences in the mechanism of
contraction associated with different receptor agonist as a contributing
factor to differences in NO responsiveness. The NO-donor (Z)-1-[N-
2-aminoethyl-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate
(DETA-NO) was selected because it slowly releases authentic NO
(19, 20), giving rise to stable relaxations at a given [DETA-NO] and
does not require biotransformation to release NO (27). In another set
of experiments, the concentration response to the natriuretic peptide
receptor A agonist ANP was determined in both TSM and PASM after
KCl-induced contraction. A KCl concentration sufficient to result in a
submaximal contraction was used in all cases. This was determined by
initially contracting the strip to maximal isometric force with KCl
(
40 mM), reducing the bath KCl to 23 mM, which resulted in
isometric force that was 50  10% of the maximal value (see Fig. 2).
The concentration responses were cumulative for all but ANP in TSM.
This was because of the transient nature of the ANP-induced relax-
ation in TSM contracted with submaximal KCl. Accordingly, each
TSM strip received a single concentration of ANP (1010 to 106 M
in single log steps), and the maximal extent of relaxation for a given
ANP concentration was recorded.
cGMP measurements. At the specified condition, PASM and TSM
strips were frozen with liquid nitrogen and stored in a 70°C freezer.
Strips were then homogenized, and the soluble extract was assayed for
cGMP using a commercially available RIA kit (Amersham Bio-
sciences, Piscataway, NJ) as previously described (32). The protein
concentration in the tissue homogenate was determined by the method
described by Lowry et al. (26), with BSA dissolved in 1 N NaOH as
the standard. [cGMP]i was expressed in picomoles per milligram
protein.
Time course for the effects of ANP on isometric force and [cGMP]i.
Eight strips were prepared from the same tissue (PASM or TSM) and
mounted in tissue baths. One strip was not contracted and served as an
untreated control. The other seven strips were contracted with sub-
maximal KCl as described above to achieve stable contractions. One
strip was not exposed to ANP and served as the contracted, untreated
control. The other six strips were exposed to the ANP concentration,
resulting in 
90% relaxation (109 M for PASM, 106 M for TSM).
The effect of 100 M 	-phenyl-1, N2-etheno-8-bromoguanosine-
3,5-cyclic monophosphorothioate (Rp-isomer), a membrane-per-
meant, phosphodisesterase resistant cGK inhibitor, on relaxation to
ANP in PASM and TSM was determined in three strips. Strips were
flash-frozen for subsequent cGMP measurements at 3, 5, 10, 15, 20,
and 40 min for PASM and at 0.5, 1, 2, 5, 7.5, and 10 min for TSM,
a time course based on previous observations (33).
cGKI mRNA sequencing. Total RNA was obtained from PASM and
TSM treated with RNAlater (Ambion, Austin, TX), which was then
flash frozen and ground under liquid nitrogen and then suspended in
guanidinium isothiocyanate; total RNA was then isolated by sedimen-
tation through CsCl) (5). RNA quality was assessed by RNA electro-
phoresis on an agarose gel. Only samples that had ratios of 28S to 18S
ribosomal RNA bands that were at least 1.2, with little evidence of
laddering below or between these bands, were studied. We isolated
mRNA from total RNA using Micro-Fast Track (Invitrogen) and then
reverse transcribed using avian myeloblastosis virus reverse transcrip-
tase (Clontech, Mountain View, CA). The resulting cDNA was probed
with rapid amplification of cDNA ends (Clontech), using adapter
sequences and a sequence that is present in both cGKI isoforms
expressed in smooth muscle (30), cGKI (40), and cGKI	 (45). The
two cGKI isoforms present in smooth muscle are alternative splice
variants sharing all but exon 1. A probe designed against the 3 end of
either cGKI isoform will detect mRNA for both cGKI isoforms. This
sequence for cGKI, nucleotides 1596–1623 of the human sequence
(40) (accession no. D45864), was used as the initial probe for
touchdown PCR. The resulting cDNA band was purified from an
agarose gel and subcloned into pCR2.1 vector by using TOPO TA
cloning kit (Invitrogen). We tested positive Escherichia coli colonies
for the insert with colony PCR using M13 forward and reverse
primers. Plasmid containing the insert was purified from a broth
culture of a positive colony using Wizard plasmid miniprep (Promega,
Madison, WI). The sequence of the insert was initially characterized
with M13 forward and M13 reverse primers by using the Sanger
dideoxy method (35) at the Mayo Rochester DNA Sequencing and
Synthesis Core Facility (Rochester, MN). These sequences were used
to generate new primers to extend the sequence until the complete
open frame was obtained. Overlapping sequences were used to design
gene-specific sequencing primers for obtaining the full-length open
reading frame sequence for porcine cGKI in triplicate. The resulting
cGKI sequence was submitted to the National Center for Biotechnol-
ogy Information (accession no. DQ119109). Oligonucleotide probes
and primers were synthesized at the Mayo Rochester Core Facility.
Oligonucleotide primers designed on the basis of a published se-
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quence were also used to probe for cGKII isoform (43) (accession no.
L12460) in PASM and TSM.
Measurement of cGKI mRNA expression. cDNA was prepared from
total RNA from PASM and TSM taken from separate animals and
stored at 20°C. Quantitative RT-PCR was used for this determina-
tion (1, 11). The exogenous internal standards (mimes) were derived
from pBR322 and composite primers (Table 1) for PCR amplifying
these were synthesized. The pBR322 sequence was selected to have a
melting point by nearest neighbor estimation (Oligo Software, Cas-
cade, CO) within 2°C of the cGKI sequence being amplified. The
respective sizes of the mime/cGKI amplicon sequences were 347/229
bp. The amplified mime sequences were purified and subcloned into
pCR2.1 plasmid by using TOPO TA cloning (Invitrogen), and colo-
nies containing the mime insert were selected as described above in
the DNA sequencing section. Plasmid was purified from the E. coli
pellet with QIAfilter plasmid maxi kit (Qiagen, Valencia, CA). Con-
firmation of insertion was obtained by sequencing the plasmid and
testing for amplification using cGKI primers that would detect total
cGKI (cGKI  cGKI	). We used 260-nm optical density to quan-
titate plasmid and mime concentrations. Mime cDNA concentrations
for determination of cGKI cDNA concentration in total RNA from
TSM and PASM were 0.05, 0.1, 0.25, 0.5, and 0.75 amol. This mime
concentration range was determined in preliminary studies and re-
sulted in cDNA sample band intensities that lay within the range of
band intensities resulting from these mime concentrations. Samples
underwent PCR for 30 cycles with the following cycling conditions:
30-s initial denaturation at 94°C, followed by 25 cycles of 10-s
denaturation at 94°C and 2 min 30 s annealing and extension at 68°C
with a final extension at 72°C for 3 min. The PCR products were run
on a 2.5% composite agarose gel [1.5% low melting point ultrapure
agarose  1% ultrapure agarose (Invitrogen)] containing 500 ng/ml
ethidium bromide for staining. We used an AlphaInnotech ChemIm-
ager 400 imaging system to digitize gels and analyzed the resulting
images by using Optiquant software (Perkin Elmer, Boston, MA). We
determined the amount of gene-specific mRNA using linear regres-
sion analysis of a plot of log (intensity mime/intensity sample) vs. log
(mol mime in PCR reaction). The point at which the regression line
crosses zero on the y-axis determines the number of moles of cGKI
mRNA present in the original total RNA sample. The quantity of
gene-specific mRNA is expressed in attomoles per microgram total RNA.
Measurement of cGK protein concentrations. Strips were flash-
frozen by rapid immersion in liquid nitrogen and stored at 70°C
until proteins were to be extracted. Then they were placed in a chilled
mortar on dry ice and pulverized, and the resulting powder was
suspended in extraction buffer of (in mM) 10 KH2PO4, pH 7.0, 1
DTT, 1 EDTA, 1 PMSF, 5 NaF, 1 g/ml leupeptin, and 1 g/ml
pepstatin A. The sample was centrifuged at 4,000 g for 10 min to
pellet insoluble material. Protein concentration in the extraction buffer
supernatant was determined with the Bradford method (2); 2.0 g of
soluble protein from the tissue extracts were loaded into wells, and
0.1, 0.3, 0.67, 1, 1,67, and 3 ng of purified cGKI (Promega) were
loaded into adjacent lanes to generate a standard curve. Proteins were
separated by electrophoresis in SDS-7.5% polyacrylamide precast
minigels (Bio-Rad) with the use of Tris-glycine-SDS buffer. The
proteins were transferred to a polyvinylidene difluoride membrane for
45 min at 100 V, and the membrane was subsequently washed with 10
mM Tris-buffered saline containing 5% (wt/vol) BSA for 15 min
(25°C). The membrane was then treated overnight with Tris-buffered
saline containing 0.2% Tween 20 and 1:20,000 dilution of cGKI
polyclonal rabbit antibody directed against the COOH terminus
shared by both cGKI and cGKI	 (StressGen Biotechnology, San
Diego, CA). After membranes were washed, they were treated with
1:10,000 anti-rabbit horse radish peroxidase-conjugated IgG antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min and then
washed again. Membranes were then treated with enhanced chemilu-
minescence Western blotting reagents (ECL; Amersham) for 1 min,
apposed to Kodak BioMax film, and developed for a period of time
that avoided saturation of any bands. The film was scanned and
digitized with the use of Adobe Photoshop and subsequently analyzed
with Optiquant software (Packard Instruments).
Measurement of cGKI activity. cGKI activity in tissue extract was
determined by measuring phosphate transfer from ATP to a cGK-
selective substrate, bovine lung cGMP-binding cGK-specific phos-
phodiesterase NH2-terminal peptide (BPDEtide; RKISASEFDRPLR)
(7, 41). Strips were frozen in liquid nitrogen and pulverized while on
dry ice. The resulting powder was suspended in ice-cold homogeni-
zation buffer composed of (in mM) 10 sodium phosphate, pH 7.0, 1
EDTA, 1 DTT, 250 sucrose, 1 PMSF, 1 g/ml pepstatin A, and 1
g/ml leupeptin for 30 min. The suspension was then centrifuged for
20 min at 12,000 g and 4°C. The supernatant was saved, and the
protein concentration was determined with the Bradford assay (2). For
phosphotransferase activity measurements, 10 l of the 
1 mg/ml
tissue extract were added to 50 l of phosphotransferase assay
mixture of (in mM) 0.2 ATP, 10 magnesium acetate, 20 Tris, pH 7.4,
0.5 isobutylmethylxanthine, 10 DTT, 10 sodium fluoride, 1 M
PKI5–24, 
250 cpm/pmol [-32P]ATP, with 60 M BPDEtide as the
cGK-selective substrate. The [cGMP] in the assay mixture was varied
from 0.01 to 100 M in half-log steps; 1 M synthetic peptide
inhibitor of cAMP-dependent protein kinase (4), PKI5–24 (TTYAD-
FIASGRTGRRNAIHD), was also added to the reaction mixture.
After a 10-min reaction time at 30°C, the reaction was terminated by
transfer of 25 l of the assay mixture to 1-in.2 section of Whatman
P-81 phosphocellulose. The phosphocellulose sections were washed
in 800 ml of 75 mM phosphoric acid three times and then once with
95% ethanol. Dried phosphocellulose sections were placed in scintil-
lation vials and counted by Cerenkov radiation on a Beckman
LS6000IC counter. All data were obtained in triplicate and averaged.
Calculated phosphotransferase activity was reported (in pmol Pi
transferred min1 mg1 protein and pmol Pi transferred min1 
ng1 cGKI) in the tissue extract used in the cGKI assay. To examine
the extent to which the phosphotransferase reaction was selective for
cGKI, a set of experiments was performed in the presence or absence
of 10 M cGMP, 100 M Rp-isomer, a membrane-permeant, phos-
phodiesterase-resistant cGK inhibitor (Alexis Biochemicals, Lausen,
Switzerland), or 10 M cAMP.
Materials. The NO-donor DETA-NO was purchased from Alexis
Biochemical (Ann Arbor, MI). BPDEtide and PKI5–24 were synthe-
sized by the Mayo Protein Core Facility. Unless otherwise specified in
the text, all other drugs and chemicals were purchased from Sigma
(St. Louis, MO). All drugs and chemicals were dissolved in distilled
water, except for the cGK inhibitor Rp-isomer, which was dissolved in
50% DMSO in water.
Table 1. Oligonucleotide composite primer sequences
Sequence
Nucleotide No.
cGKI pBR322
Sense AAGGGGGATTGACATGATAGAATTTCCGATCGTTGTCAGAAGTAAGTTGG 1930–1956 3734–3756
Anti CGAACACAGACACCCACTACGTTGTGGGGTTACATCGAACTGGATCTC 2158–2133 4028–4007
Composite primer sequences showing sequences used to probe for cGMP-dependent protein kinase I (cGKI) subunit cDNA and mime constructed from cGKI
subunit sequence (accession no. DQ119109)  specified pBR322 sequence (bold).
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Statistical analysis. Data are expressed as means  SE; n repre-
sents the number of pigs. The effects of ANP on isometric force and
[cGMP]i were assessed by repeated-measures ANOVA with post hoc
analysis using Student-Newman-Keuls method. cGKI mRNA expres-
sion, cGKI protein expression, and phosphotransferase activities be-
tween PASM and TSM were compared by unpaired Student’s t-test.
A P value  0.05 was considered statistically significant. Concentra-
tion-response curves were compared by nonlinear regression analysis,
as described by Meddings et al. (29). In this method, force (F) at any
concentration of drug (C) is given by the equation F  FmC/(EC50 
C), where Fm represents the maximal isometric force and EC50
represents the concentration that produces half-maximal isometric
force for that drug. Nonlinear regression analysis was used to fit
values of Fm and EC50 to data for F and C for each condition studied.
This method allows comparison of curves to determine whether they
are significantly different and whether this overall difference can be
attributed to differences in Fm, EC50, or both parameters. A P value
0.05 was considered statistically significant. The apparent Vmax and
EC50 for cGMP in the phosphotransferase studies were determined in
the same manner.
RESULTS
Physiological studies. In both PASM and TSM, after an
initial submaximal contraction with 
23 mM KCl, the relax-
ation to DETA-NO was stable (data not shown) at each
concentration and was complete at the highest concentration.
The log EC50 (M) for DETA-NO was significantly less for
PASM than with TSM (Fig. 1) (6.55  0.11 and 5.37 
0.13, respectively, P 0.01), a result similar to that previously
reported for canine PASM and TSM (22).
Addition of 109 M ANP in PASM submaximally con-
tracted with KCl resulted in a stable reduction in force (Fig.
2A). Addition of 106 M ANP resulted in an initial decrease in
isometric force in TSM that partially recovered (Fig. 2B). ANP
produced concentration-dependent relaxation of both PASM
and TSM (Fig. 3), but both sensitivity and maximal responses
were much greater in PASM than in TSM (EC50 of 0.066 
0.027 and 13.2  2.3 nM, respectively; P  0.001).
The relaxation caused by 109 M ANP in PASM was
generally associated with no significant increase in steady-
state, [cGMP]i, with the exception of the measurement at 15
min after ANP administration (Fig. 4A). By 40 min, [cGMP]i
was indistinguishable from baseline (pre-ANP) values, despite
persistent 
80% relaxation. In contrast, the modest relaxation
Fig. 1. Effects of the nitric oxide (NO) donor (Z)-1-[N-2-aminoethyl-N-(2-
ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO) on isometric
force in pulmonary artery smooth muscle (PASM) and tracheal smooth muscle
(TSM). Strips were contracted to half-maximal isometric force with KCl. Data
are means  SE; n  6 pigs.
Fig. 2. Isometric force tracings for PASM (A) and TSM (B), illustrating the
protocol used to determine the effect of atrial natriuretic peptide (ANP) on
isometric force. Strips were initially contracted to near maximal contraction with
40 mM KCl and then contracted to 
50% maximal with 23 mM KCl. After this
contraction reached a plateau value, the specified amount of ANP was added to the
tissue bath. The relaxation to ANP was sustained in PASM but was biphasic in TSM.
Fig. 3. Effects of ANP on isometric force in PASM and TSM. Strips were contracted
to 50% of maximal isometric force with
23 mM KCl, and the concentration response
to ANP was determined in a cumulative fashion for PASM and the specified individual
concentrations applied to TSM. Data are means  SE; n  5 pigs.
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produced by 106 M ANP in TSM was accompanied by an
increase in [cGMP]i that reached a maximum at 2 min after
ANP administration, increasing by 
10-fold over baseline
values (Fig. 4B). Although the increase in [cGMP]i was greater
in TSM than in PASM, the extent of relaxation was signifi-
cantly lower in TSM. After the peak increase in TSM, [cGMP]i
decreased and was accompanied by an increase in isometric
force; 100 M cGK inhibitor decreased relaxation to the above
specified concentrations of ANP in PASM and TSM by 92 
9 and 95  15%, respectively (n  3).
Expression studies. The mRNA sequence was determined
for cGKI in porcine trachea and was 96% homologous to
cGKI mRNA expressed in human vascular (40) and bovine
tracheal (44) smooth muscle (accession nos. D45864 and
X16086, respectively). The inferred porcine cGKI amino acid
homology and identity were 98 and 99.5% compared with both
the human inferred and known bovine amino acid sequences.
The predicted molecular mass of porcine cGKI was 76,372 Da.
Quantitative competitive RT-PCR successfully amplified both the
constructed mime cDNA and the sample cDNA (Fig. 5A, inset).
Serial dilutions of mime produced linear changes in band intensity
that bracketed the intensity of cGKI-selective bands (Fig. 5B). The
expression of total cGKI was determined by this means because
all cGKI isoforms have identical mRNA and amino acid se-
quences in the region sampled by the primer pair used in these
studies (Table 1). cGKI mRNA expression relative to total RNA
(Fig. 5B) was greater in PASM than in TSM (2.23  0.36 vs.
0.93 0.31 amol mRNA/g total RNA, respectively; P 0.01).
An example of an SDS-PAGE result in which tissue homog-
enate was loaded into lanes adjacent to a set of six concentra-
tions of purified cGKI is shown in Fig. 6A, inset. Although
both cGKI isoforms could be detected by the COOH-terminal-
Fig. 4. Time course of the effects of ANP on isometric force and on tissue [cGMP] in PASM (A) and TSM (B). Data are means  SE; n  6 pigs. *Isometric
force differed significantly from the initial control at time  0 s. †Tissue cGMP differed significantly from the initial control at time  0 s.
Fig. 5. Total cGMP-dependent protein kinase I (cGKI) mRNA expression in PASM and TSM using quantitative competitive RT-PCR. A: method for determining
the amount of cGKI found in PASM and TSM using a known amount of mime cDNA sequence as an internal standard. Solid lines, linear least squares fit with
r2  0.99. Data are means  SE, n  6 pigs. Dashed line, point in the curves at which mime is equal to the sample; this value is determined for each sample
by interpolation. Inset: example of an ethidium bromide agarose gel with mime cDNA bands above sample bands. B: semiquantitative measurement of total cGKI
mRNA present in PASM and TSM. *Amount of cGKI is greater in PASM (P  0.018). Data are means  SE; n  6 pigs.
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directed antibody used, only one band is observed, running in
the same location as purified cGKI. A plot of arbitrary
intensity units vs. the concentration of purified cGKI resulted
in a nonlinear standard curve best fit with a sigmoid curve.
Equal loading of tissue homogenate protein resulted in nearly
identical values for cGKI protein in both PASM and TSM in
the example shown in Fig. 6A. A summary of the results from
six experiments indicated no significant difference in the
amount of cGKI protein present in the soluble fraction of tissue
homogenates from PASM and TSM (0.56  0.07 and 0.49 
0.04 ng cGKI/g protein, respectively).
Phosphotransferase enzyme activity studies. In the initial
studies, basal phosphotransferase activity obtained in the pres-
ence of a potent cGK inhibitor was 101  25 pmol min1 
mg1 protein in the soluble fraction of PASM tissue homog-
enate (Fig. 7). This increased to 880  10 pmol min1 mg1
in the presence of 10 M cGMP; 100 M Rp-isomer, a potent
cGKI inhibitor, decreased the phosphotransferase activity and
inhibited the cGMP-induced increase in this activity by70%;
10 M cAMP significantly increased phosphotransferase ac-
tivity but much less so than equimolar cGMP.
Phosphotransferase activity was not significantly different
between PASM and TSM in the absence of added cGMP. This
activity was increased with increasing [cGMP], with an appar-
ent EC50 of 1.2  0.2 M for homogenates from both tissues
(Fig. 8A). Maximal phosphotransferase activity, however, was
significantly greater in PASM compared with TSM (899  78
vs. 462  76 pmol min1 mg1; P  0.001). When normal-
ized to the amount of cGK present in the tissue homogenates
used for these assays, the maximal phosphotransferase activity
of cGKI was also significantly higher in PASM than in TSM
(1.61  0.15 and 1.04  pmol min1 ng cGKI1; P  0.05)
(Fig. 8B). There was no significant difference in phosphotrans-
ferase activity indexed to cGKI protein in PASM and TSM
when no cGMP was added to the assay mix. The maximal
phosphotransferase activity obtained for PASM and TSM was

50% and 30% that of purified cGKI. The apparent cGMP
EC50 for purified cGKI was significantly lower than that
obtained in tissue samples (0.17  0.04 M; data not shown).
DISCUSSION
In agreement with a previous study in canine PASM and
TSM, the NO donor DETA-NO caused complete relaxation in
porcine PASM and TSM after a standardized contraction to
KCl, resulting in 
50% of maximal isometric force (22).
PASM was nearly an order of magnitude more sensitive to this
NO donor than TSM. The increased NO sensitivity was pre-
viously related, in part, to increased cGMP production at a
given NO donor concentration because of greater expression
and activity of sGC in PASM. Greater relaxation at a given
[cGMP]i is another mechanism that could contribute to a
greater NO responsiveness in PASM than in TSM. This was
not addressed in our previous study (22) because in both
tissues, increases in steady-state [cGMP]i were not detected
with up to 90% relaxation. There are, however, two additional
methods by which cGMP sensitivity may be assessed in dif-
ferent tissues: use of cGK agonists and use of an alternative
Fig. 6. Total cGMP-dependent protein kinase I (cGKI) protein in the soluble fraction of tissue homogenates from PASM and TSM using a semiquantitative
immunoblotting method. A: representative data using known amounts of purified bovine lung cGKI to create a standard curve and 2 g of homogenate from
each tissue. Inset: representative experiment of an immunoblot used to generate the standard curve and tissue data points (P, PASM; T, TSM). B: semiquantitative
measurement of total cGKI in PASM and TSM. Data are means  SE; n  6 pigs.
Fig. 7. Phosphotransferase activity in a soluble PASM homogenate. 0 cGMP,
no cGMP added to the assay mix. cGMP indicates 10 M cGMP; cGKi
indicates 100 M 	-phenyl-1,N2-etheno-8-bromoguanosine-3,5-cyclic
monophosphorothioate (Rp-isomer), a cGMP-dependent protein kinase inhib-
itor; cGMP  cGKi indicates 10 M cGMP  100 M cGK inhibitor; cAMP
indicates 10 M cAMP. *Activity differs significantly from the 0 cGMP
condition (P  0.025). #Activity differs significantly from that obtained in the
presence of 10 M cGMP alone (P 0.01). Data are means SE; n 4 pigs.
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endogenous system for production of cGMP, the particulate
guanylyl cyclases.
cGMP is inefficiently taken up by tissues and is subject to
rapid breakdown by intracellular phosphodiesterases. Variably
membrane-permeable cGMP, phosphodiesterase-resistant cGK
agonists have been developed to facilitate assessment of cGMP
responsiveness in tissue samples. Interpretation of concentra-
tion-response data between tissues with these agents must still
account for the possibility of differences in tissue penetration
and membrane permeability as an explanation for any concen-
tration-response differences observed. This adds an additional
complication in describing the relationship between cGK ago-
nist and isometric force in a given tissue, namely, that, al-
though the bath concentration of the cGMP analog is known,
its intracellular concentration is not.
Particulate guanylyl cyclases are an alternative system for
increasing [cGMP]i in smooth muscle independent of NO. The
natriuretic peptide receptor A activated by ANP is present in
both pulmonary artery (42) and airway smooth muscle (12),
which is reflected by ANP-induced increases in [cGMP]i in
both tissues (13, 15, 42). In the present study, the relationship
between [cGMP]i and relaxation differed significantly between
the two tissues. In PASM, 109 M ANP resulted in nearly
complete relaxation without a significant increase in the
steady-state [cGMP]i at all but one time point, a finding similar
to that obtained with an NO donor in a previous study (22). As
in that study, despite there being no significant increase in
steady-state [cGMP]i, prevention of ANP-induced relaxation
with a cGK inhibitor indicates that such relaxation is cGMP
mediated. In TSM, however, despite a nearly 10-fold increase
in [cGMP]i above baseline values, treatment with 106 M ANP
resulted in only incomplete relaxation to ANP. Similar findings
of minimal relaxation to ANP in TSM, despite significant
increases in [cGMP]i, have been previously reported (15, 33).
Of interest, in prior work, we found that when an NO donor is
used to induce relaxation in TSM, it does so without a signif-
icant increase in [cGMP]i (22, 33). Thus relaxation to cGMP in
TSM apparently depends on the location of the guanylyl
cyclase producing the cGMP. It is very sensitive to cGMP
when it is produced by soluble and insensitive when produced
by membrane bound guanylyl cyclases. Although the mecha-
nism for this is unclear, it does indicate that, under the
circumstances used in this study, the cGMP sensitivity of TSM
is significantly less than that of PASM. We cannot explain the
biphasic nature of the relaxation to ANP in TSM, which may
be accounted for by phosphodiesterase activity, rapid receptor
desensitization or cGKI target dephosphorylation. The first
possibility seems unlikely, since initial recovery of force oc-
curs at a time when [cGMP]i is increasing.
If cGMP sensitivity were to play a role in the lower NO
sensitivity of TSM vs. PASM, several predictions would be
made. The first is that cGMP responsiveness in TSM would be
lower than in PASM. Ideally, this would be examined by
establishing a relationship between the relaxant effect of an NO
donor and its concurrent effect on [cGMP]i. This is not possi-
ble for the reasons given above. However, the cGMP respon-
siveness of TSM is lower than that of PASM when ANP is
used to stimulate cGMP production by particulate guanylyl
cyclase. A second prediction would be that expression and
activity of cGK would be lower in TSM than in PASM, since
cGK is the primary enzyme transducing the cGMP signal.
No cGKII mRNA was found in either PASM or TSM, a
result that is somewhat surprising given the abundance of its
expression in lung (43). Its association with gastrointestinal
epithelium and not intestinal smooth muscle (28) suggests that
cGKII in lung is probably associated with the lung epithelial
cell layers. Total cGKI mRNA and protein expression were
determined using cDNA probes and antibodies selective for
portions of the cGKI sequence shared by both cGKI and
cGKI	. Total cGKI mRNA expression was significantly higher
in PASM than in TSM. The amount of total cGKI mRNA
expression is very similar to the values obtained for sGC
mRNA expression in TSM and PASM (22), on the order of 4
and 2 amol mRNA/g total RNA, respectively. This level of
expression does not reflect a high abundance of mRNA for
either signaling protein, but neither are they particularly rare.
The levels of cGKI mRNA expression measured in these
studies are the first semiquantitative report of their absolute
rather than their relative expression in smooth muscle tissues.
The quantitative RT-PCR method used in these studies has the
advantage of having an internal standard, but may be limited in
accuracy by variability in the quality of the mRNA in each
Fig. 8. Phosphotransferase activity in tissue homogenates from PASM and TSM. A: effect of added cGMP on the phosphotransferase activity normalized to the
amount of total protein in the tissue homogenates. Data are means  SE; n  6 pigs. *TSM phosphotransferase activity is less than that obtained for PASM
at cGMP  1 M (P  0.01). B: phosphotransferase activity at the specified cGMP concentration normalized to the amount of cGKI present in the tissue
homogenates assayed. *Phosphotransferase activity in PASM is greater than in TSM (P  0.05).
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preparation, the use of a cDNA rather than an RNA mime and
differences in the PCR efficiency between the mime insert
sequence and the cDNA produced by reverse transcription of
mRNA in a total RNA sample. Variability in the quality of
RNA was assessed before the reverse transcription step and
RNA samples showing evidence of noticeable degradation
were not reverse transcribed. The mime sequence in pBR322
was selected to have similar melting and annealing character-
istics to that of the sGC subunit sequence being probed. The
semiquantitative assessment of mRNA for each sGC subunit
demonstrated low variability across multiple total RNA prep-
arations. The possibility of systematic errors from use of a
cDNA mime and reverse-transcribed mRNA from tissue total
RNA exists and cannot be addressed with the methods used.
The values for total cGKI mRNA expression reported here are
thus relatively precise lower limits for the actual amount of
cGKI mRNA expressed in PASM and TSM.
Very little is known about the quantitative relationship
between mRNA and protein expression for cGKI within any
tissue, let alone across tissues. Total cGKI protein expression
in soluble homogenates from PASM and TSM were not sig-
nificantly different, indicating an apparent discordance be-
tween levels of cGKI expression at the mRNA and protein
levels. This apparent discrepancy may be due to either a
systematic error in one or both of the semiquantitative mea-
surements or may reflect a difference in gene transcription,
mRNA stability, or cGKI translation and turnover between the
two tissues. Of the two methods used for measuring cGKI
expression, the quantitative competitive RT-PCR method
makes more assumptions and may amplify any errors in initial
quantitation of the total RNA used in the reverse transcription.
The immunoblotting method used in this study is less suscep-
tible to such errors, although differences in extraction effi-
ciency and in protease activity between tissues could exist. The
efficiency of soluble protein extraction between the two tis-
sues, however, was similar because nearly equal protein con-
centrations were obtained in tissue homogenates from suspen-
sions of equal weights of both tissues suspended in equal
volumes of extraction buffer (data not shown). Arguing against
differences in protease activity between tissues is the observa-
tion that the cGKI homogenates from both PASM and TSM
give similar semiquantitative results over storage times of more
than 1 mo (data not shown). In further support of the general
accuracy of the semiquantitative immunoblotting methods
used in this study, the level of cGKI protein expression is of the
same magnitude as that previously reported in cultured rat
aortic smooth muscle cells (37). Thus it is likely that the
expression of cGKI in PASM and TSM is similar and a
difference in protein expression does not account for differ-
ences in cGKI activity. Finally, the assumption that the same
quantitative relationship between cGKI mRNA and protein
expression exists either in the same tissue under different
conditions or across tissues under the same conditions (i.e., that
mRNA expression is an adequate surrogate for protein
expression) may be an incorrect one and needs to be examined
in all cases.
The presence of a single-band cGKI band on the immuno-
blots of tissue homogenates and the fact that they run in a
position identical to commercially purified cGKI reported in
this study should not be taken to indicate that both cGKI and
cGKI	 are not present in PASM and TSM. The calculated
molecular mass of these proteins differs by only 1,500 Da, and
resolution of these two 75-kDa proteins under the conditions
used in these studies was not expected.
Although the levels of cGKI and sGC mRNA expressions
were similar in these tissues, there is nearly 10-fold more cGKI
than sGC protein (22) expressed in both PASM and TSM. The
functional significance of higher cGKI (primary cGMP-respon-
sive protein) vs. sGC (NO-linked cGMP production) protein
expression remains to be established.
The phosphotransferase assay used in this study (6, 7)
demonstrated a marked elevation in activity with 10 M added
cGMP that was inhibited by a cGK inhibitor; 10 M cAMP
also increased phosphotransferase activity significantly above
baseline values but to a much lesser extent (only 
20%) than
the same concentration of added cGMP. The slight activation
with cAMP probably does not indicate that cAMP-dependent
protein kinase remains active in these homogenates, since
cAMP also activates purified cGKI, but requires 
10-fold
higher concentrations to maximally activate the enzyme. To-
gether, these data indicate that the tissue homogenate phospho-
transferase assay used in these studies reflected cGK activity in
the homogenate. The phosphotransferase assay demonstrated
the expected increase in activity with increasing cGMP in both
tissues. The 
1 M EC50 for cGMP was not significantly
different between PASM and TSM but was greater than ex-
pected for a tissue containing a significant amount of cGKI.
With the use of the same phosphotransferase assay as for the
tissue homogenates, commercially purified cGKI had a nearly
10-fold lower cGMP EC50 (data not shown). Previous reports
(23, 36) indicated that cGKI	 has a cGMP EC50 similar to that
found for the phosphotransferase assay results from PASM and
TSM homogenates. However, cGKI is present in both porcine
PASM and TSM, as attested by its successful use to establish
a complete open reading frame cGKI sequence in these tissues.
A simple explanation for the cGMP EC50 results obtained in
this study is that cGKI	 is the predominant isoform expressed
in both PASM and TSM. This is apparently at odds with
previous reports in which cGKI is thought to be the predom-
inant isoform in vascular smooth muscle (25, 45). In the
absence of a significant difference in the phosphotransferase
activity cGMP EC50 between PASM and TSM, it is unlikely
that differences in the proportion of cGKI and cGKI	 could
account for differences in cGMP responsiveness between the
tissues.
The Vmax for the two cGKI isoforms are the same (23, 36).
Any differences in Vmax between PASM and TSM must there-
fore be accounted for by either differences in the amount of
total cGKI present in the two tissues or by differences in the
activity indexed to the amount of cGKI in each. The amount of
cGKI found in PASM and TSM did not differ significantly.
However, when the maximal phosphotransferase activity was
indexed to the amount of total cGKI, TSM had 
60% the
activity of PASM. This difference in apparent cGKI specific
activity suggests that the enzyme is regulated differently in the
two tissues and would decrease the cGMP responsiveness of
TSM relative to PASM. The biochemical basis of such a
difference in cGKI-specific activity is unclear but might in-
volve differences in the degree of cGKI autophosphorylation
between tissues (36). Use of the same extraction procedure and
the fact that both PASM and TSM samples were freshly
obtained and processed at the same time make differences in
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treatment of the tissue homogenates an unlikely explanation for
this finding.
In summary, the present study demonstrates that the re-
sponse to NO is greater in porcine PASM than in TSM. A
significant difference in the responsiveness of the contractile
system to the effects of cGMP, cGMP responsiveness, between
these tissues was demonstrated using the NO-independent
particulate guanylyl cyclase system, activated by ANP.
Whereas no detectable increase in [cGMP]i was observable
with nearly complete relaxation in PASM, a 10-fold increase in
[cGMP]i gave rise to only modest relaxation in TSM. Although
total cGKI mRNA expression was greater in PASM, total
protein expression was not significantly different between the
tissues. The apparent cGKI specific activity, however, was
significantly lower in TSM than in PASM, a novel finding that
would be expected to result in decreased cGMP responsiveness
in TSM. The difference in response to NO between these
tissues may thus be accounted for by both lower cGMP
production (22) and cGMP responsiveness in TSM. It is
possible that these differences in the NO-cGMP signaling
system may play a significant role in reported differences in the
therapeutic response to NO between airways and the pulmo-
nary arterial circulation.
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